Clinical Trials Browser

Phase 2 × Waldenstrom Macroglobulinemia × daratumumab × Clear all

NCT03679624 2023-10-23

Daratumumab Plus Ibrutinib in Patients With Waldenstrӧm's Macroglobulinemia

Phase 2 Terminated

1 enrolled 8 charts

Hypergammaglobulinemia, Waldenstrom Macroglobulinemia, Recurrence

NCT03187262 2022-11-23

A Study of Daratumumab in Patients With Relapsed or Refractory Waldenström Macroglobulinemia

Phase 2 Completed

13 enrolled 11 charts

Waldenstrom Macroglobulinemia